Diagnostic and Therapeutic Approach to Autoimmune ...



Rituxan/Rituxamab 26 Peer Reviewed Studies to show NOT Investigational Or Experimental 8 Specific Studies include dosing and frequency 2 recommend FDA Approve for Autoimmune EncephalitisDiagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders By: A. Sebastian López-Chiriboga, MD1 Eoin P. Flanagan, M 2018The Diagnosis and Treatment of Autoimmune Encephalitis by: Dr. Eric Lancaster(Includes dosing/frequency) 3 Autoimmune Encephalopathy by: Eoin P. Flanagan, M.B.B.Ch.; Richard J. Caselli, M.D. (Includes dosing/frequency) Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study (Dalmau 577 cohort study) Protocol for Autoimmune Encephalitis is well established in this large study (Includes dosing/frequency) Autoimmune encephalitis: a case series and comprehensive review of the literature (Includes dosing/frequency) Paraneoplastic and Other Autoimmune Disorders of the Central Nervous System By: Andrew McKeon, MD(Includes dosing/frequency) include print outs of: Table 4. Common Immunotherapies Used to Treat Autoimmune CNS Disorders 2? Acute Treatment and Chronic Maintenance Therapy (dosing/frequency) limbic encephalitis Topic Editor?Alexander Rae-Grant, MD(dosing/frequency) DEMENTIAS AND ENCEPHALOPATHIES Andrew McKeon, Vanda A. Lennon, Sean J. Pittock (includes dosing/frequency) ___________________________________________________________________________Rituximab in Autoimmune CNS DiseaseAuthors: J Gordon Millichap,John J MillichapStudy recommends Rituximab should be approved by FDA” Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS. Benefit was reported in 125 (87%) patients, greater in patients treated early. The off-label use of rituximab should be restricted to disorders having significant morbidity and mortality.” and safety of rituximab in pediatric autoimmune and inflammatory CNS diseaseBy: Dr. RC DaleStudy recommends Rituximab should be approved by FDA“CONCLUSION:While limited by the retrospective nature of this analysis, our data support an off-label use of rituximab, although the significant risk of infectious complications suggests rituximab should be restricted to disorders with significant morbidity and mortality.” Antibody-Mediated Encephalitis Josep Dalmau, M.D., Ph.D., and Francesc Graus, M.D., Ph.D. 2018New Advances in Pediatric Neurologic and Developmental Disorders in the Era ...By Gyula Acsadi “Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.”_________________________________________________________________________________________________________________________________A clinical approach to diagnosis of autoimmune encephalitis By: Dr. Grau, Dr. Dalmau(15)00401-9/fulltextAutoimmune Encephalitis in ChildrenBy: Thaís Armangue, MD, ?Mar Petit-Pedrol, BS, and?Josep Dalmau, MD, PhD Published 2012“Most children receive first line of immunotherapies including corticosteroids, intravenous immunoglobulin, or plasma exchange. However, because these treatments fail in 30% to 40% of the patients, and because there is an increasing number of reports showing that rituximab is effective, this drug is increasingly being used in combination with intravenous immunoglobulin and steroids, or after first-line immunotherapies”______________________________________________________________________________Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort Neurology?2016;86:18?1683-1691_________________________________________________________________________________________________________________Autoimmune Encephalitis — New Awareness, Challenging Questions by: ?Dr. Sarosh R Irani and Dr. Angela Vincent encephalitis update By: Josep Dalmau?and?Myrna R. Rosenfeld*Also discusses overlapping Demyelinating Disorders16. Management of anti-N-methyl-D-aspartate receptor encephalitis in childrenZHONG Jian-Min Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognitionBy: Luigi Zuliani1,2,?Francesc Graus3,?Bruno Giometto1,?Christian Bien4,?Angela Vincent2 Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease By: Dr Matthew S. Kayser, M.D., Ph.D. and Dr Josep Dalmau, M.D., Ph.D. ______________________________________________________________________________Antibody-Mediated Autoimmune Encephalopathies and ImmunotherapiesBY; Matteo Gastaldi,#?Ana?s Thouin,#?and?Angela Vincent Diagnosis of Autoimmune Encephalopathies, Dementias, and EpilepsiesBy: Mayo Clinic Laboratories treatment for autoimmune limbic encephalitis in an institutional cohortWoo-Jin Lee, MD Effectivel Treats Autoimmune Encephalitis: Presented at ANAby: Thomas S. May _____________________________________________________________________________________Immune therapy in?autoimmune encephalitis: a systematic reviewBy: Nosadini M,?Mohammad SS,?Ramanathan S,?Brilot F,?Dale RC. Management of anti-N-methyl-D-aspartate receptor encephalitis in childrenZhong JM. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download